| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD153; CD30L; CD30LG; TNLG3A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human TNFSF8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于CXCL11抗体的参考文献示例(内容为模拟概括，仅供参考)：
1. **文献名称**：*CXCL11 Antibody-Based Detection of Tumor Microenvironment in Colorectal Cancer*
**作者**：Smith A, et al.
**摘要**：研究通过抗CXCL11抗体检测结直肠癌组织中CXCL11的表达水平，发现其高表达与免疫细胞浸润和患者生存率改善相关，提示其作为潜在预后标志物。
2. **文献名称**：*Neutralizing CXCL11 Activity Attenuates Autoimmune Inflammation in Lupus Models*
**作者**：Chen L, et al.
**摘要**：利用CXCL11中和抗体阻断趋化因子功能，显著减少系统性红斑狼疮模型小鼠的炎症反应和肾脏损伤，表明靶向CXCL11可能为自身免疫病治疗策略。
3. **文献名称**：*Development of a High-Specificity Monoclonal Antibody for Human CXCL11*
**作者**：Wang Y, et al.
**摘要**：研究成功制备并验证了一种高特异性抗人CXCL11单克隆抗体，适用于ELISA、免疫组化和流式细胞术，为临床样本分析提供可靠工具。
4. **文献名称**：*CXCL11 Expression in Viral Infections: Insights from Antibody-Mediated Localization*
**作者**：Garcia R, et al.
**摘要**：通过抗CXCL11抗体定位发现，病毒感染(如HCV)诱导的CXCL11在肝组织中的异常表达与Th1免疫应答相关，为抗病毒治疗提供新靶点。
(注：以上为模拟内容，实际文献需通过PubMed、Google Scholar等平台检索确认。)
CXCL11. also known as interferon-inducible T-cell alpha chemoattractant (I-TAC) or IP-9. is a small chemokine belonging to the CXC subfamily. It plays a critical role in immune responses by binding to the G-protein-coupled receptor CXCR3 and atypical chemokine receptor ACKR3 (CXCR7). CXCL11 is primarily produced by monocytes, dendritic cells, and endothelial cells in response to proinflammatory cytokines like IFN-γ. It facilitates the recruitment of activated T cells, natural killer (NK) cells, and other immune cells to sites of inflammation, infection, or tissue injury.
CXCL11 antibodies are essential tools for detecting and quantifying this chemokine in research and diagnostic applications. They enable studies on its involvement in inflammatory diseases (e.g., rheumatoid arthritis, psoriasis), autoimmune disorders (e.g., multiple sclerosis), and cancer progression, where CXCL11 may promote tumor immune evasion or angiogenesis. Specific monoclonal or polyclonal antibodies are used in techniques such as ELISA, Western blotting, immunohistochemistry, and flow cytometry to analyze protein expression, localization, and signaling pathways.
Recent therapeutic strategies explore CXCL11-neutralizing antibodies to modulate excessive immune activation or disrupt CXCR3/ACKR3 interactions in pathological conditions. However, its dual pro- and anti-tumor roles in different microenvironments highlight the need for context-specific antibody applications. Research continues to clarify its complex regulatory mechanisms and therapeutic potential.
×
